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Abstract: Integrins have been reported to mediate cell survival, proliferation, differentiation, and migration programs. For 
this reason, the past few years have seen an increased interest in the implications of integrin receptors in cancer biology and 
tumor cell aggression. This review considers the potential role of integrins in cancer and also addresses why integrins are 
present attractive targets for drug design. It discusses of the several properties of the integrin-based chemotherapeutic agents 
currently under consideration clinically and provides an insight into cancer drug development using integrin as a target.
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Introduction
Integrins are a large family of eukayotic cell-surface receptors that mediate dynamic interaction between 
cells and extracellular adhesion molecules (Humphries, 2000). The integrins recognize extracellular 
matrix (ECM) proteins or counter-receptors on adjacent cells. ECM molecules that affect cell adhesion 
include glycoproteins such as ﬁ  bronectin (Fn) (Gardner and Hynes, 1985), von Willebrand factor (vWF) 
(Chow et al. 1992), vitronectin (Vn) (Pytela et al. 1985), thrombospondin (Tsp) (Karczewski et al. 
1989), tenascin (Tn) (Joshi et al. 1993), collagen (Coll) (Heino, 2000), laminin (Ln) (Burgeson and 
Christiano, 1997), osteopontin (Opn) (Green, 2001), and other unidentiﬁ  ed molecules. A key ﬁ  nding 
in the discovery of the integrins was that the well known amino acid sequence Arg-Gly-Asp (RGD) 
which was initially found in ﬁ  bronectin, serves as a primary cell recognition motif. Subsequently, the 
RGD sequence was found in many ECM molecules and, in many cases, was responsible for cell attach-
ment (Karczewski et al. 1989; Joshi et al. 1993; Ruggeri et al. 1983; Davis, 1992; Schnapp et al. 1995; 
Kimura et al. 1998). The recent crystal structures of the extracellular domains of αVβ3 (Xiong et al. 
2001; 2002) have provided new insights into integrin activation and ligand recognition. The interaction 
of integrins with their ligands is dependent upon signals transduced from the cytoplasmic tails to the 
extracellular domains (Travis et al. 2003). The binding of integrins to their ligands is critically impor-
tant to many diverse physiological phenomena, such as attachment, cell proliferation (Miyata et al. 
2000; Hollenbeck et al. 2004; Hedin et al. 2004; Zhou et al. 2004), migration (Hirsch et al. 1996; Sakai 
et al. 1998; Fujiwara et al. 2001; Paulhe et al. 2001). Integrins also contribute to the initiation and/or 
progression of many diseases including tumor invasion, angiogenesis and metastasis (Tsuji et al. 2004; 
Takanami et al. 2005; Guo et al. 2005; Enserink et al. 2004; Chung et al. 2004; Felding-Habermann 
et al. 2002; Gladson et al. 1996; Zheng et al. 1999; Zheng et al. 2000).
Integrin Family
Integrin family have atleast 18 α- and 8 β-subunits that are known to comprise least 24 members (Berman 
et al. 2000; Parise et al. 2000; Humphries, 2000; Hynes, 2002). Additionally, in a recent survey of human 58
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genome, 24 α- and 9 β-subunits have been identi-
ﬁ  ed (Venter et al. 2001), which implies 6 novel 
α- and 1 novel β-subunits. However, their exis-
tence is not yet ﬁ  rmly established. Integrins are 
found in many species, ranging from sponges to 
mammals (Brower et al. 1997; Gettner et al. 
1995).
Cell adhesion requires integrin occupancy. The 
binding of integrins to their ligands has been inten-
sively studied employing proteolytic fragments 
and synthetic peptides corresponding to selected 
regions in Fg, Fn and several other matrix compo-
nents (Table 1).
As shown in Table 1, the two distinct subunits 
form noncovalent heterodimers where each subunit 
has a large extracellular domain (700–100 resi-
dues), a single transmembrane domain and a short 
cytoplasmic domain (20–70 residues). The excep-
tion to this is the β4 subunit which has an extended 
cytoplasmic domain containing four Fn type III-
like domains (Colombatti et al. 1993). All integrin 
dimers are dissociated by ionic detergents, indicat-
ing that the subunits are noncovalently held 
together.
The α subunits are subdivided into two groups 
based on some structural differences. The ﬁ  rst 
group is comprised of the α1, α2, αD, αE, αL, αM 
or αX subunits, respectively. The second group is 
composed of α3, α4, α5, α6, α7, α8, α9, α10, α11, 
αIIb or αV subunits, respectively, and is bridged by 
a disulphide bond with an exceptional α4 subunit 
subjected to a post translational cleavage at a site 
close to the transmembrane domain of the precur-
sor. Thus, there are two chains linked by a disul-
phide bridge, a light chain and a heavy chain. The 
light chain is composed of the cytoplasmic domain, 
the transmembrane region and a part of the extra-
cellular domain (about 25 kD), while the heavy 
chain contains the rest of the extracellular domain 
(about 120 kD). Integrin α4 is unique among all 
known integrin α subunit sequences in that it (i) 
has neither an inserted I-domain, nor a disulﬁ  de-
linked C-terminal fragment, and (ii) a potential 
protease cleavage site, near the middle of the extra-
cellular portion of the polypeptide rather than close 
to the transmembrane domain of other integrin α 
subunits (Xiong et al. 2001, 2002).
The β1 integrins generally mediate interaction 
between cells and ECM (Perlino et al. 2000). The 
β2 integrins subfamily including αLβ2, αMβ2, αXβ2, 
αDβ2, are immunologically restricted to leukocytes 
and typically have other cell surface molecules as 
Table 1. The integrin family of proteins and their 
ligands.
β1
α1 Colls, laminins
α2 Colls, laminins, chondroadherin
α3 Laminins (such as laminin-1, -5, -8, -10, 
and -11), Fn, thrombospondin, TIMP-2, 
uPAR, collagen, epiligrin, entactin
α4 Fn, VCAM
α5 Fn, Fg, uPAR
α6 Laminins, merosin (laminin α2 chain), 
kalinin
α7 Laminins, merosin (laminin α2 chain),
α8 Fn, vitronectin, Tn-C, osteopontin, and 
nephronectin
α9 angiostatin, Tn-C, osteopontin, and 
ADAMs, VCAM-1, tTG,
α10 Colls
α11 Colls
αV Fn, vitronectin
β2
αL ICAM-1, -2 and -3
αM Fg, ICAMs, iC3b, factor-Xa, denatured 
ovalbumin
αX Fg, iC3b
αD VCAM, ICAMs
β3
αIIb Coll, Fn, vitronectin, Fg, vWF, 
thrombospondin
αV Fn, vitronectin, Fg, vWf, 
thrombospondin, FGF-2, MMP-2 and 
some ADAM proteins
β4
α6 Laminins
β5
αV Vitronectin, uPAR
β6
αV Fn, Tn
β7
α4 Fn, VCAM, MAdCAM
αE E-cadherin
αV Colls, laminins, Fn
βN
αV Fn, Colls
β8
αV Vitronectin, Fn
The various heterodimeric combinations of α and β subunits. 
Abbreviations used are: Colls: collagens; Fn: ﬁ  bronectin; TIMP-2: tissue 
inhibitor of metalloproteinase; uPAR: urokinase-type plasminogen 
activator (uPA) receptor; VCAM: vascular cell adhesion molecule; 
Fg: fibrinogen; Tn-c: tenacin-C; ADAMs: a disintegrin and 
metalloproteinase proteins; tTG: tissue-type transglutaminase; iC3b: 
inactivated complement component 3b; ICAM: intercellular cell 
adhesion molecule; vWf: von Willebrand factor; FGF-2: ﬁ  broblast 
growth factor 2; MMP: matrix metallo-proteinases and MAdCAM: 
mucosal addressin cell adhesion molecule.59
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their ligands, for example, αLβ2 interacts with 
counter receptors ICAM-1, ICAM-2, and ICAM-3 
(Marlin and Springer, 1987; de Fouerolles and 
Springer, 1992; Binnerts et al. 1996; Woska et al. 
1996) while αMβ2 recognizes iC3b (Wright and 
Silverstein, 1983), ﬁ  brinogen (Zhang and Plow, 
1996) and neutrophil inhibitory factor (NIF) 
(Muchowski et al. 1994). There are two integrins 
αIIbβ3 and αVβ3 in integrin family, that share the 
common β3 subunit, have been reported to function 
as promiscuous receptors for the RGD-containing 
adhesive proteins such as ﬁ  brinogen, vitronectin, 
ﬁ  bronectin, von Willebrand factor, and thrombos-
pondin (Scarborough et al. 1999). The β4 integrin 
facilitates key functions of carcinoma cells, includ-
ing their ability to migrate, invade, and evade 
apoptosis (Folgiero et al. 2007). The β5, β6, β7, β8 
and βN subunits can form a dimmer with an αV 
subunit binding to different ligands (Table 1) and 
showing different functions.
Integrin Structure
The first three-dimensional structure of the 
extracellular domain of an integrin was published 
in October 2001, a decade and a half after the 
family was ﬁ  rst deﬁ  ned (Xiong et al. 2001, 2002, 
2004) (Fig. 1).
Crystal structure of integrin αVβ3 showing the 
dimer and individual subunits (Xiong et al. 2002). 
An unliganded ectodomain from the αA-lacking 
integrin αVβ3 contains the two subunts assembled 
into a globular head built by two predicted domains: 
the N-terminal seven-bladed propeller domain of 
αV and an αA-like domain (βA) from the β3. βA 
loops out from the “Hybrid” domain (β3 residues 
55–108 and 353–432), which itself is inserted in 
the N-terminal plexin/semaphorin/integrin (PSI) 
domain (residues 1–54 and residues 433–435) of 
β3. The PSI domain and the beta-tail domain (βTD), 
together forming the β3 leg. Ig-like thigh domain 
and calf-1 and calf-2 domains formed the αV leg. 
Two legs are bent at the “knees” and folded back 
against the head of the same molecule. This sharp 
bending takes place between the thigh and calf-1 
of αV (α-genu) and approximately corresponding 
to between EGF domains 1 and 2 of β3 (β-genu). 
A metal ion (Ca
2+ or Mn
2+) occupies the α-genu on 
both the ligand and unliganded structures. At the 
base of propeller, blades 4–7 each contain a metal 
ion coordinated in a β-hairpin loop.
Integrin and Cancer
Cancer occurs when cells become abnormal and 
keep dividing and forming more cells without 
control or order. If cells keep dividing when new 
cells are not needed, a mass undifferentiated tissue 
forms. This mass of extra tissue, called a growth 
or tumour, can constitute either a benign or a 
malignant tumour respectively. Benign tumors can 
usually be removed and, in most cases, they do not 
Figure 1. Structure of the extracellular segment of αVβ3 derived with permission from Xiong et al. 2002. (A) Bent conformation of αVβ3 as it 
was present in the crystal. (B) Extension of the structure to reveal its domains.60
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come back. Most importantly, cells from benign 
tumors do not spread to other parts of the body. 
Benign tumors are rarely a threat to life. In contrast, 
malignant tumours are truly cancerous. Cancer 
cells can invade and damage nearby tissues and 
organs. Cancer cells can break away from a malig-
nant tumor and enter the bloodstream or the lym-
phatic system. The spread of cancer is called 
metastasis which appears to be a complex multi-
step process that involves the invasion of cancer 
cells from primary neoplasm followed by their 
dissemination through the lymphatic vessels and 
systemic circulation. New blood vessels form 
either by vasculogenesis, which refers to initial 
events of vascular growth in which endothelial cell 
precursors (angioblasts) differentiate and assemble 
into primitive vessels or by angiogenesis, which 
refers to a combination of sprouting of new vessels 
from pre-existing ones, and longitudinal separation 
of pre-existing vessels in a process named intus-
susception (Conway et al. 1993). The angiogenesis 
can be triggered in pathological conditions such as 
tumor growth and chronic wounding. Angiogenetic 
process involves functional cooperativity between 
cytokines and endothelial cell (EC) surface integ-
rins. Cell bound integrins by their physical interac-
tion with ligands necessary are essential for cell 
adhesion, migration and positioning, and induce 
signaling events essential for cell survival, prolif-
eration and differentiation. They also trigger a 
variety of signal transduction pathways which are 
involved in mediating invasion, metastasis and 
squamous-cell carcinoma which can be reviewed 
as follows. The review focuses mainly on speciﬁ  c 
α and β subtypes which have been most exten-
sively investigated in cancer.
β1 class of integrins
Although little clear correlation between tumor 
formation, invasion and β1 integrin expression has 
yet been demonstrated in human patients, it has 
been possible to show a crucial role of β1 integrin 
in tumor formation and metastasis in mice. Tumor 
cells expressing β1 integrin formed signiﬁ  cantly 
larger primary tumors and had a dramatically 
increased metastasis into liver and lung (Brakebusch 
et al. 1999). In another study, which used a T cell 
lymphoma line in which both β1 integrin alleles 
was deleted by homologous recombination, 
metastasis formation in mice was signiﬁ  cantly 
reduced (Stroeken et al. 2000). Recently, it was 
shown that ablation of the β1 integrin gene in 
mammary epithelium dramatically impaired mam-
mary tumorigenesis in mice (White et al. 2004). 
Sudhakar et al. have reported that human collagen 
α1(IV)NC1 binds to α1β1 integrin, competes with 
type IV collagen binding to α1β1 integrin, and 
inhibits migration, proliferation, and tube forma-
tion by ECs, indicating that α1 (IV)NC1 is a 
potential therapeutic candidate for targeting tumor 
angiogenesis (Sudhakar et al. 2005). A study using 
β1 integrin double knockout lymphocytes and 
retransfection of β1 integrin deletion mutants have 
shown that different parts of the cytoplasmic 
domain of β1 integrin are required either for adhe-
sion or for invasion and metastasis (Stroeken et al. 
2000).
Integrin α1β1 and α2β1 were shown to regulate 
hepatocarcinoma cell invasion across the ﬁ  brotic 
matrix microenvironment (Yang et al. 2003). A 
potent selective inhibitor of α1β1 integrin, obtus-
tatin puriﬁ  ed from the venom of the Vipera lebetina 
obtusa viper was reported to have a marked ability 
to inhibit angiogenesis in vivo in the chicken cho-
rioallantoic membrane assay, and in the Lewis lung 
syngeneic mouse model (Marcinkiewicz et al. 
2003). Grzesiak and Bouvet have demonstrated 
that the certain cancer cell lines including CFPAC 
(a ductal epithelioid cell line established from a 
cystic ﬁ  brosis patient with pancreatic adenocarci-
noma), BxPC-3 (human pancreas adenocarci-
noma), Colo-357 (human lymph node metastasis), 
and Panc-1 (Pancreatic Cancer Cell Line) attach 
to 3D type I collagen scaffolds in an α2β1-speciﬁ  c 
manner and that this integrin-speciﬁ  c adhesion is 
required for subsequent cell proliferation. Such 
evidences support the notion that targeting α2β1 
integrin-speciﬁ  c type I collagen adhesion may have 
therapeutic value in the treatment of pancreatic 
cancer (Grzesiak and Bouvet, 2007). Integrin α2β1 
was also reported to mediate the anti-angiogenic 
and anti-tumor activities of angiocidin, a novel 
tumour-associated protein which is capable of 
binding to both α2β1 and type I collagen. This 
protein promoted α2β1-dependent cell adhesion 
and inhibited tumor growth and angiogenesis 
(Sabherwal et al. 2006). Combined antagonism of 
α1β1 and α2β1 was shown to reduce tumor growth 
substantially as well as angiogenesis of human 
squamous cell carcinoma xenografts (Senger et al. 
2002).
The interaction of α3β1 with ligand laminin-5 
has been demonstrated to promote the migration 61
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and invasion of malignant glioma and melanoma 
cells (Tsuji, 2004; Tsuji et al. 2002; Giannelli et al. 
2007) and to promote binding to virus glycopro-
tein. A signiﬁ  cant increase in proliferation and 
adhesion in response to collagen 1 and laminin for 
integrin receptor α3β1 was also observed in ovarian 
cancer cell lines (Ahmed et al. 2005). More 
recently, uPAR (urokinase-type plasminogen acti-
vator receptor), and TIMP (tissue inhibitors of 
metalloproteinases)-2 were also proposed as 
ligands of α3β1 integrin in mediating uPA/uPAR 
interaction and intracellular signaling (Wei et al. 
2007). In an animal model it was shown that 
soluble uPAR antagonizes cancer progression 
(Jo et al. 2003).
The Src family kinases are classiﬁ  ed as onco-
genic proteins due to their ability to activate cell 
migration (Rodier et al. 1995; Rahimi et al. 1998) 
in many cell types including epithelial tumor cells. 
Studies with chimeric α4 integrin subunits have 
shown that α4 cytoplasmic domain can enhances 
cell migration via c-Src activation (Chan et al. 
1992; Hsia et al. 2005).
α5β1 integrin interacts with Fn which is impli-
cated in several cellular activities including cell 
proliferation, differentiation, and migration. A 
high-afﬁ  nity interaction that occurs with the cen-
tral cell binding domain, a region involved in 
many fundamental aspects of cell growth and 
morphogenesis, is dependent on the RGD 
sequence and other recognition sequences (Li 
et al. 2003; Murillo et al. 2004). The interaction 
with Fn has been demonstrated with both lung 
epithelial cells and ﬁ  broblasts. In addition, the 
inhibition of cell surface α5 integrin expression 
was found to decrease phosphoinositide-3 kinase 
(PI3K) activity and inhibit colon cancer cell 
attachment, suggesting that agents which selec-
tively target α5 integrin subunit expression may 
enhance the effects of standard chemotherapeutic 
agents and provide a novel adjuvant treatment for 
selected colon cancers (Lopez-Conejo et al. 
2002). Furthermore, cells expressing the α5β1 
integrin displayed a dramatic enhancement in the 
ability of growth factors to activate PI3K and 
protein kinase B (PKB), indicating this stimula-
tion may also involve the interaction between 
α5β1 and the PI3 K and PKB signalling pathways 
(Lee et al. 2000). Wei et al. recently reported that 
urokinase receptor binding to α5β1 is required for 
maximal responses to Fn and tumor cell invasion 
(Wei et al. 2007). Kuwada et al. demonstrated that 
expression of integrin α5β1 in colon cancer cells 
decreases HER (human epidermal growth factor 
receptor)-2-mediated proliferation, crystal violet 
assays were showing inhibition of the cell prolif-
eration of Caco-2 control cells with the antago-
nistic HER-2 antibody mAb 4D5 (Kuwada et al. 
2005). MAb 4D5 is also indicated clinically active 
in cancer patients to target HER2-overexpression 
(Baselga et al. 1996; Rhodes, 2005). Furthermore, 
mAb 4D5 has been shown great promise as tar-
geted agents in the treatment of patients with 
cancer (Bartsch et al. 2007).
It has been reported that α6 integrin-mediated 
neutrophil migration through the perivascular 
basement membrane (PBM) is platelet-endothelial 
cell adhesion molecule1 (PECAM-1) dependent, 
a response associated with PECAM-1-mediated 
increased expression of α6β1 on transmigrating 
neutrophils (Dangerﬁ  eld et al. 2002). Signiﬁ  cantly 
increased ovarian cancer cell line proliferation and 
adhesion to collagen 1 and laminin (ligands of 
integrin receptor α6β1) were also reported (Ahmed 
et al. 2005). In addition, an α6 integrin is found to 
be overexpressed in human oesophageal carcinomas, 
suggesting an important role in oesophageal tumor 
invasion (Tanaka et al. 2000). This notion has since 
been conﬁ  rmed by other studies (Mercurio et al. 
2001; Demetriou et al. 2004).
The α7β1 integrin is a laminin-binding receptor 
that was originally identified in melanoma 
(Kramer et al. 1991). Ziober et al. reported that 
during melanoma progression, acquisition of a 
highly tumorigenic and metastatic melanoma 
phenotype is associated with loss of the α7β1 
(Ziober et al. 1999). Integrin α7β1 serves an 
important mechanical function in the diaphragm 
by contributing to passive compliance, viscoelas-
ticity, and modulation of muscle contractile prop-
erties (Lopez et al. 2005).
Integrin α10β1 is a major collagen-binding inte-
grin during cartilage development and in mature 
hyaline cartilage while α11β1 was originally found 
in fetal muscle (Gullberg et al. 1995). Integrin α11β1 
recognizes the triple-helical GFOGER sequence 
(where single letter amino acid nomenclature is 
used, O = hydroxyproline) found in interstitial col-
lagens (Tulla et al. 2001). Little is known about the 
biology of these recently identiﬁ  ed integrins. Inte-
grin α10β1 is expressed on chondrocytes and some 
ﬁ  brous tissues. Integrin α11β1 is involved in cell 
migration and collagen reorganization in mesen-
chymal non-muscle cells (Tiger et al. 2001). 62
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Recently, α11β1 integrin is required on periodontal 
ligament ﬁ  broblasts for cell migration and collagen 
reorganization by assisting axial tooth movement 
(Popova et al. 2007).
αV class of integrin
The ﬁ  rst integrin found associated with tumor 
angiogenesis was αVβ3 (Eliceiri et al. 1998; 
Eliceiri, 2001; Ruegg et al. 2003). Integrin αVβ3 
has a broad distribution and is found on endothelial 
cells, smooth muscle cells (SMCs) and hemato-
poietic cell types such as platelets and osteoclasts. 
The interaction of αVβ3 with its ligands plays a 
crucial role in angiogenesis and neointimal forma-
tion after vascular injury. In addition, during 
osteoclast-mediated bone resorption, αVβ3 regu-
lates the cytoskeletal organization required for cell 
migration and formation of the sealing zone 
(McHugh et al. 2000). Prostate cancer speciﬁ  c 
integrin αVβ3 was demonstrated to modulate bone 
metastatic growth and tissue remodeling (McCabe 
et al. 2007). The study of co-expression of bone 
sialoprotein, integrin αVβ3, and MMP-2 in papil-
lary thyroid carcinoma cells demonstrated that 
cancer cells appear to become more invasive when 
bone sialoprotein forms a cell-surface trimolecular 
complex that links MMP-2 to integrin αVβ3 
(Karadag et al. 2004). Bayless et al. present very 
convincing data showing that integrin αVβ3 as well 
as integrin α5β1 regulate human endothelial cell 
vacuolation and lumen formation, implicating a 
major role contributed by these two integrins for 
endothelial cell morphogenesis (Bayless et al. 
2000). It is also clear that the integrin αVβ3 plays 
an important role in virtually every stage of cancer 
progression. Indeed, neuroblastoma aggressiveness 
has been identiﬁ  ed to be correlated with the expres-
sion of integrin αVβ3 and αVβ5 by microvascular 
endothelium (Erdreich-Epstein et al. 2000). Other 
studies also demonstrate that increased αVβ3 
expression level is closely associated with 
increased cell invasion and metastasis (Feldin-
Habermann et al. 2002). Li et al. reported that 
antisense αV suppressed tumour growth more 
strongly than antisense β3, antisense therapy but 
simultaneous targeting at both integrin subunits 
was more effective than the respective mono-
therapies (Li et al. 2007). Integrin αVβ3 has been 
demonstrated to interact with the activated forms 
of the platelet-derived growth factor, insulin, and 
vascular endothelial growth factor (VEGF) cell 
receptors faciliting optimal activation of cell 
proliferative signalling pathways (Giancotti and 
Ruoslahti, 1999; Kumar, 2003). The functional 
activity of αvβ3 on endothelial and tumor cells 
may well be regulated by VEGF (Byzova et al. 
2000). VEGF has been also implicated in prostate 
carcinogenesis and metastasis as well as in angio-
genesis. Both VEGF and its receptor are expressed 
by prostate carcinoma cells at a high level (Ferrer 
et al. 1998; 1999).
A role for αVβ6-mediated production in the 
regulation of MMP-9 and MMP-3 have been 
reported in several tumor types and in untrans-
formed keratinocytes (Ramos et al. 2002; Ahmed 
et al. 2002). MMP-9 plays a critical role in the 
recruitment of bone marrow derived CD45 posi-
tive cells into the primary tumor and the establish-
ment of a mature vasculature (Jodele et al. 2005). 
Integrin αVβ6 also plays a role in wound healing 
and cancer of the oral cavity (Thomas et al. 2006). 
In addition, αVβ6 has been implicated in the regu-
latory control of the uPA proteolytic cascade 
(Ahmed et al. 2002). A gradual increase in the 
expression of αVβ6 integrin from borderline to 
malignant tumors has been reported in oral squa-
mous carcinomas (Jones et al. 1997) and breast 
carcinomas (Arihiro et al. 2000). In malignant 
keratinocytes and colon cancer cells, increased 
expression of this integrin enhances MMP-9 secre-
tion and MMP-9-mediated invasion (Thomas et al. 
2000; Agrez et al. 1999). Inhibition of αVβ6 func-
tion using inhibitory antibodies results in total 
abrogation of MMP-9 activation (Thomas et al. 
2001) suggesting that the expressions of αVβ6 
integrin and MMP-9 are linked, and their coordi-
nate expression appears to promote invasion by 
squamous and colon carcinoma cells. The integrin 
αVβ6 interacts with Fn, Vn (Huang et al. 1998), 
tenascin (Weinacker et al. 1995), and latency-
associated peptide (Munger et al. 1999), a protein 
derived from the N-terminal region of the trans-
forming growth factor(TGF)-β gene product that 
mediates cell adhesion, spreading, migration, 
proliferation, and activation of latent TGF-β 
(Weinreb et al. 2004; Thomas et al. 2001).
Until recently, there has been little information 
about integrin αVβ8 which has been reported to 
function as an additional receptor for foot-and-
mouth disease virus (FMDV) (Jackson et al. 2004) 
in addition to the three RGD-dependent integrins 
αVβ1, αVβ3, and αVβ6, which have been shown to 
be receptors for FMDV previously (Jackson et al. 
1997, 2000, 2002; Duque et al. 2004). Notably, 63
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αVβ8 as well as αVβ6 may promote epithelial-
mesenchymal transition (EMT) by contributing to 
the activation of TGF-β (Munger et al. 1999). 
Additionally, αVβ8—mediated activation of TGF-β 
was shown to block the proliferation of certain 
cancer cells (Mu et al. 2002). Several recent stud-
ies have demonstrated that both up-regulation and 
down-regulation of expression of αV  integrins and 
other integrins can be effective markers of malig-
nant diseases and patient prognosis.
Although there are few reports of enhanced 
expression of αIIbβ3 (than of αVβ3) integrin in 
tumour cells, one observation indicated an impor-
tant role in tumour progression. A study on human 
melanoma biopsies showed that αIIbβ3 expression 
increased with tumour thickness (Trikha et al. 
2002a). In addition, a single pretreatment of human 
melanoma cells with c7E3 Fab, an αIIbβ3 antibody 
inhibited lung colonization of the tumor cells in 
severe combined immunodeﬁ  cient mice (Trikha 
et al. 2002b).
Other sub-classes of integrins
Parathyroid hormone-related protein (PTHrP) was 
reported to not only increase transcriptional activ-
ity of the integrin subunit α5 (Anderson et al. 2007) 
but also upregulate integrin α6β4 expression and 
activate Akt in breast cancer cells (Dittmer et al. 
2006; Shen and Falzon, 2006; Shen et al. 2007). 
Falcioni et al. ﬁ  rst identiﬁ  ed a tumor antigen (TSP-
180) associated with metastasis that was shown to 
be identical to the β4 integrin subunit (Falcioni 
et al. 1997; Kennel et al. 1989). Subsequently other 
studies showed that expression of α6β4 persists in 
some aggressive carcinomas and that its expression 
may be linked to the behavior of these tumors (Guo 
et al. 2004). At earlier of the year in 2001, Davis 
and his colleagues demonstrated that α6β4 integrin 
has an inﬂ  uence on tumour biology as this integrin 
and its ligand, laminin-5, are essential gene prod-
ucts for the maintenance and remodeling of a 
stratiﬁ  ed epithelium (Davis et al. 2001). The β4 
integrin, for example, was lost in the lesions of 
prostatic intraepithelial neoplasia together with 
basal cell-lining and in prostate carcinoma the 
expression of β4 integrins was totally lost (Davis 
et al. 2001). In normal skin keratinocytes, expres-
sion of the α6β4 integrin is restricted to the prolif-
erative basal layer and mediates stable adhesion to 
the underlying basement membrane. Observations 
in carcinoma cells show a functional and spatial 
dissociation of the α6β4 integrin from the 
hemidesmosomal complex, which stimulates cell 
migration and, therefore, may contribute to carci-
noma invasion (Kippenberger et al. 2004). Indeed, 
many carcinomas express elevated levels of α6β4 
(Herold-Mende et al. 2001), particularly breast 
carcinomas (Chung and Mercurio, 2004).
Pawar et al. recently have shown that the uPA-
mediated cell surface cleavage of the alpha6 
integrin extracellular domain is involved in tumor 
cell invasion and migration on laminin (Pawar 
et al. 2007). In addition, observations in carcinoma 
cells show a functional and spatial dissociation of 
the α6β4 integrin from the hemidesmosomal com-
plex, which stimulates cell migration (Kippen-
berger et al. 2004). Furthermore, blocking 
antibodies to either α6 or β4 integrin subunits sup-
press the formation of apoptosis-resistant acinar 
structures in Matrigel by mammary epithelial cells 
(Weaver et al. 2002), suggesting a role for β4-
mediated cellular polarity in mediating antiapop-
totic signaling. Integrin α6β4 was recently noted 
only at the cell’s basal interface with the basement 
membrane in normal pancreatic ducts. But in 
pancreatic adenocarcinomas, 92% demonstrated 
overexpression of integrin α6β4 and altered local-
ization to the cytoplasm and membranous regions, 
this upregulation and redistribution of integrin 
α6β4 expression implicated a role of integrin in 
pancreatic adenocarcinoma progression (Cruz-
Monserrate et al. 2007). Interestingly, the 
expression of β4 was inversely correlated with 
dissemination of ten human gastric cancer cell 
lines in SCID (severe combined immunodeﬁ  -
ciency) mice (Ishii et al. 2000). In addition, strong 
evidence suggests that reduced expression of α6 
and β4 subunits may contribute to the higher 
tumorigenicity of androgen-independent prostate 
tumor cells (Bonaccorsi et al. 2000).
Several key signalling molecules in carcinoma 
cells are also involved in the mechanisms of α6β4 
integrin-mediated tumour behaviour (Bon et al. 
2007; Folgiero et al. 2007) since β4 has been 
demonstrated to interact with ERBB2 (erythroblastic 
leukemia viral oncogene homolog 2, encoding an 
185-kDa, 1255 amino acids, orphan receptor tyrosine 
kinase) that displays potent oncogenic activity when 
overexpressed) in some cultured breast tumour cells, 
and the two proteins synergize in promoting cellular 
proliferation and invasion (Falcioni et al. 1997). In 
addition, Guo et al. established that integrin α6β4 
may be required for mammary tumourigenesis driven 64
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by the expression of ErBB2 (Guo et al. 2006). 
Folgiero et al. revealed that α6β4 can regulate the 
expression of ErBB-3 at the level of protein 
translation, resulting in a signiﬁ  cant induction of 
ErBB-2/ErBB-3 heterodimerization and consequent 
activation of PI3K (Folgiero et al. 2007; Liu et al. 
2007). Introduction of β4 in β4-negative breast 
carcinoma cells activates signalling from PI3K to 
Rac (a member of the Rho family of small guanosine 
triphosphatases) and increases the invasion of these 
cells in vitro (Shaw, 2001).
The integrin αEβ7 (also known as cell marker 
CD103) is expressed by most intra-epithelial lym-
phocytes (IEL). An important ligand for this mol-
ecule is the epithelial cell adhesion molecule 
E-cadherin. Cresswell et al. have demonstrated that 
the up-regulation of integrin αEβ7 by lymphocytes 
increases adhesion to E-cadherin expressing blad-
der cancer targets, indicating a role of integrin αEβ7 
in cancer invasion (Cresswell et al. 2002).
Integrins as Targets 
for the Treatment of Cancer
From what has been discussed above, integrins 
play a key role in tumor angiogenesis and cancer. 
Because they are cell surface receptors interacting 
with extracellular ligands, they represent ideal 
pharmacological targets. A variety of integrin 
antagonists such as low molecular weight inhibi-
tors, peptidomimetics, or monoclonal antibodies 
are in various stages of development as anti-cancer 
therapeutics (Kerr et al. 2002; Mousa 2002; Tucker 
et al. 2003).
In-vivo study has demonstrated that the addition 
of inhibitory anti-β1-integrin antibodies or the 
re-expression of α2β1 integrins leads to the rever-
sal of the malignant phenotype in a 3-dimensional 
cell culture model and to a reduction in tumour 
formation in animal models (Zutter et al. 1995). 
Yao et al. recently show that β1 integrin expression 
has potential prognostic value in invasive breast 
cancer and that coexpression of ﬁ  bronectin may 
help identify patients with more aggressive tumors 
who may beneﬁ  t from targeted therapy (Yao et al. 
2007). More studies have been focused on αVβ3, 
since αVβ3 has been identiﬁ  ed as a prognostic 
indicator of survival and a speciﬁ  c potential target 
for control of angiogenesis, therapies directed 
against integrin against αVβ3, have been developed 
(Brooks et al. 1994; Gladson et al. 1996; Zhang 
et al. 2007; Gramoun et al. 2007).
Antibodies Against Integrins 
as Inhibitors
MEDI-552
Brooks and his coworkers first showed that a 
monoclonal antibody speciﬁ  c for αVβ3, MEDI-552 
(LM609), could block angiogenesis in a murine 
model (Brooks et al. 1994). In addition, there is an 
ongoing phase I dose escalation study evaluating 
the safety of MEDI-522 in patients with advanced 
malignancies. This antibody was chosen for its 
unique ability to selectively target multiple and 
different cell types. In a phase I trial on various 
solid tumours, MEDI-522 appeared to be without 
signiﬁ  cant toxicity (McNeel et al. 2005). MEDI-
522 was detectable both in quiescent and in angio-
genically active skin blood vessels as well as in 
the dermal interstitial space. The levels of phos-
phorylated focal adhesion kinase (pFAK) were 
reduced during MEDI-522 treatment, suggesting 
a modulating effect on this signaling molecule 
(Zhang et al. 2007; Gramoun et al. 2007).
CNTO 95
A fully humanized monoclonal antibody to anti-αV 
integrins, CNTO 95, has been shown to inhibit 
angiogenesis and tumor growth in preclinical stud-
ies (Mullamitha et al. 2007). CNTO 95 is likely 
to be less immunogenic in humans compared to 
chimeric or humanized antibodies (Trikha et al. 
2004). CNTO 95 bound to puriﬁ  ed αVβ3 and αVβ5 
with higher afﬁ  nity (a Kd of approximately 200 
pM and to αV integrin-expressing human cells with 
a Kd of 1–24 nM). In vitro, CNTO 95 potentially 
inhibited human melanoma cell adhesion, migra-
tion and invasion (doses ranging 7–20 nM) and 
appeared to be safe without inhibition of normal 
physiologic angiogenesis (Martin et al. 2005; 
Trikha et al. 2004).
17E6
The 17E6 antibody strongly perturbs cell attach-
ment mediated by αV associated integrins, by 
reacting with αVβ3, αVβ5, and αVβ1, and has the 
ability to disrupt stable interaction between vit-
ronectin and αVβ3, and blocks the growth of M21 
tumours in nude mice. In two nude mouse tumor 
models, injection of 17E6 strongly inhibited 
tumor development (Mitjans et al. 2000; Mitjans 
et al. 1995).65
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Integrin antibodies that block speciﬁ  c integrins 
for treatment of cancer are still in clinical trial 
stages as lessons should be learnt from integrin 
antibodies for the treatment of other diseases. For 
example, Tysabri (also called natalizumab), an 
antibody which blocks α4 integrins and inhbits the 
α4-mediated adhesion of leukocytes to their 
counterreceptor (s) (Minagar et al. 2000; O’Connor 
et  al. 2004, 2005). Although the specific 
mechanism(s) by which tysabri exerts its effects 
in multiple sclerosis (MS) have not been fully 
characterized, Tysabri was initially approved by 
the Food and Drug Administration (FDA) in U.S.A. 
in November, 2004 for the treatment of patients 
with relapsing forms of MS, but was withdrawn 
by the manufacturer three months later after three 
patients developed progressive multifocal leuko-
encephalopathy (PML), a serious viral infection of 
the brain, in the drug’s clinical trials, FDA then put 
clinical trials of the drug on hold, allowing them 
to resume a year later after conﬁ  rming that there 
were no additional cases of PML. In June 2006, 
the FDA resumed marketing of Tysabri with a 
restricted distribution program. Tysabri is indicated 
for use as monotherapy, because we do not know 
enough about how its use with other immune 
modifying drugs could impact risk. (www.fda.
gov/cder/drug/infopage/natalizumab).
Other antibodies
α1β1 and α2β1 integrins play a signiﬁ  cant role in 
the VEGF-driven angiogenesis. Ha 31/8 and Ha 
1/29 are antibodies against α1 and α2 integrin 
subunits which were reported to inhibit endothelial 
cells in a gradient of immobilized collagen I assay 
(haptotaxis) by 40%, whereas the combination 
of both antibodies synergized to reach 90% 
inhibition (Alghisi and Ruegg, 2006). Consistent 
with these results, administration of both the anti-
α1 and the anti-α2 antibodies to nude mice bearing 
a human A431 squamous cell carcinoma xenograft 
suppressed angiogenesis by 60% and tumor 
growth by 40% (Senger et al. 2002). Interest-
ingly, preclinical studies with monoclonal 
antibodies (MAbs) against lactadherin, a glyco-
protein of the milk fat globule membrane was 
found that there was a clear increase in VEGF-like 
proangiogenic activity (Taylor et al. 1997; 
Silvestre et al. 2005) when lactadherin is added 
back exogenously to the ischemic muscles. An 
investigation has further identiﬁ  ed lactadherin as 
a physiological ligand of αVβ3 and αVβ5, thus 
conﬁ  rming a proangiogenic activity of these inte-
grins in the VEGF-dependent neovascularization 
in adult mice, but not in embryos. Animal test 
showed that the expression of Flk-1 (VEGFR-2) 
is elevated in β3-deﬁ  cient mice, indicating that 
αVβ3 can control the amplitude of the VEGF 
response by controlling the Flk-1 level or activity 
(Reynolds et al. 2004). In vitro, anti-α5β1 func-
tion-blocking mAbs (NKI-SAM-1, JBS5, or IIA1) 
inhibited adhesion in a 72% to 100% range 
depending on the cell line used. This result was 
further conﬁ  rmed in vivo in an angiogenesis assay 
treated with ﬁ  broblast growth factor 2 (Kim et al. 
2000). The anti-α5β1 M200 antibody (Volocix-
imab) is another chimeric monoclonal antibody 
of α5β1 integrin that blocks tumor growth and 
metastasis. M200 binds to α5β1 integrin on acti-
vated endothelial cells with high binding afﬁ  nity 
and inhibits in vitro tube formation induced by 
VEGF and/or bFGF, suggesting a mechanism of 
action independent of growth factor stimulus. In 
fact, inhibition of α5β1 function by M200 induced 
apoptosis of actively proliferating, but not resting 
endothelial cells (Ramakrishnan et al. 2006).
Disintegrins, RGD-Based Peptides 
and Small Molecule Integrin 
Antagonists
The “disintegrin” terminology was initially applied 
in 1990 to describe a family of cysteine-rich, RGD-
containing proteins from viper venom toxins that 
inhibit platelet aggregation and integrin-mediated 
cell adhesion (Gould et al. 1990; Niewiarowski 
et al. 1994; McLane et al. 2004). Studies of RGD-
containing proteins in venom toxins have been 
found that a number of them, such as contortro-
statin, salmosin and bitistatin (Markland et al. 
2001; Zhou et al. 1999; Swenson et al. 2004; 
Golubkov et al. 2003; Kang et al. 1999; Chung 
et al. 2003; McQuade et al. 2004), are able to 
inhibit tumor growth and angiogenesis. Echistatin 
has been found to induce a decrease of both auto-
phosphorylation and kinase activity of pp125FAK, 
suggesting inhibitory activity in processes integral 
to angiogenesis, such as cell growth, survival, and 
migration (Della et al. 2000). Triﬂ  avin was found 
to interact with either αIIbβ3 on platelet membranes, 
resulting in inhibition of platelet adhesion, secre-
tion, and aggregation in injured arteries, or αVβ3 
on SMCs subsequently inhibiting cell migration 66
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and proliferation (Sheu et al. 2001). Triﬂ  avin also 
blocks neuronal sprouting and the induction of 
hyperalgesia induced by peripheral nerve injury (Fu 
et al. 2004). Recently, soluble RGD peptides have 
been demonstrated to induce apoptosis by inducing 
conformational changes in procaspases, leading to 
increased oligomerization and subsequent autopro-
cessing of these enzymes (Buckley et al. 1999). In 
addition, RGD-containing proteins from venom 
toxins (e.g. salmosin, contortrostatin, rhodostomin 
and accutin) were also found to induce apoptosis 
(Chung et al. 2003; Zhou et al. 1999; Wu et al. 
2003; Yeh et al. 1998). It is still not clear whether 
these proteins’ apoptotic induction is through inter-
action with integrins or through a different apoptotic 
pathway since Jan et al. in a recent issue of Cell 
have shown that integrins may regulate apoptosis, 
through caspase-independent mechanisms (Jan 
et al. 2004). These data have shown the potential 
for these RGD-containing snake venom proteins to 
function as integrin antagonists as well as anti-
angiogenic and antimetastatic compounds, leading 
to drug development for therapeutic usage (Mark-
land et al. 2001; Kerr et al. 2002; Hallahan et al. 
2001; Coller, 2001).
The integrins that bind to RGD peptides are 
generally over-expressed in angiogenic vessels. In 
certain cancer, the tumor cells also express RGD-
binding integrins. A vast body of preclinical and 
clinical literature exists on the use of RGD-based 
integrin antagonists in cardiovascular disease and 
cancer (Tucker, 2003; McQuade and Knight, 2003; 
Kumar et al. 2003; Shimaoka and Springer, 2004). 
A cyclic pentapeptide called EMD66203 [cyclic 
L-Arg-L-Gly-L-Asp-D-Phe-L-Val (RGDfV) pep-
tide or cyclo(-Arg-GlyAsp-D-Phe-Val)](Aumailley 
et al. 1991) was shown preferential inhibition of 
vitronectin binding to the αVβ3 rather than to the 
αIIbβ3 (Frieser et al. 1996). Further modiﬁ  cation of 
the EMD66203 led to the synthesis of EMD121974, 
an RGD-containing pseudopeptide (c(RGDfV)) or 
cyclo(Arg-Gly-Asp-D-Phe-[NMe]Val) also known 
as cilengitide (Dechantsreiter et al. 1999). Struc-
tural study revealed that the D-amino acid in this 
peptide is found preferentially in position i + 1 of 
a β II’ turn, a characteristic for its biological activ-
ity. EMD121974 is also a dual αVβ3/αVβ5 integrin 
antagonist with interesting biochemical and bio-
logical features to be tested in cancer therapy 
(Belvisi et al. 2005, 2006). The crystal structure of 
the extracellular segment of integrin αVβ3 in com-
plex with EMD121974 revealed that the pentagonal 
peptide inserted into a crevice between the 
propeller and βA domains on the integrin head 
(Xiong et al. 2002). EMD 121974 was demonstrated 
to be an αV-integrin antagonist and a potent 
inhibitor of angiogenesis, by inducing apoptosis 
of growing endothelial cells through inhibition of 
their αV-integrin interaction with the matrix proteins 
vitronectin and tenascin (Taga et al. 2002).
ST1646, an RGD-containing pseudopeptide, 
is a potent, highly selective αVβ3/αVβ5 integrin 
antagonist, equipotent to or more potent than the 
well-characterized integrin antagonists c(RGDfV) 
(Belvisi et al. 2006; Haier et al. 2002). The struc-
ture docking model for the ST1646-αVβ3 complex 
has conﬁ  rmed that, similarly to the crystal struc-
ture of the EMD121974-αVβ3 complex, the ligand 
seems to interact mainly through electrostatic 
forces in a rather shallow cleft and that essentially 
no hydrophobic interactions can be observed 
(Belvisi et al. 2005). In an in vitro anti-angiogenic 
activity assay, ST1646 inhibited HUVEC 
proliferation with potency similar to EMD121974 
(IC50, 2.9 and 4.4 µmol/L for the two compounds, 
respectively). The inhibitory effect was revers-
ible. In an in vivo antiangiogenic activity assay 
as determined by daily administration of ST1646 
(30 µg/embryo) with CAM (chick chorioallantoic 
membrane) assay at day 9 via a gelatin sponge 
implant and at day 12 for histologic analysis, 
showed signiﬁ  cant inhibition of the angiogenic 
response triggered by both FGF2 and VEGF 
(p  0.001) (Belvisi et al. 2005).
SCH 221153, an RGD-based peptidomimetic, 
inhibits the binding of the disintegrin, echistatin to 
αVβ3 and αVβ5 with similar potency, according to 
IC50 values of 3.2 nM and 1.7 nM, respectively 
(Kumar et al. 2001). SCH 221153 inhibits FGF2 
and VEGF-induced endothelial cell proliferation 
in vitro according to IC50 equal to 3–10 µM (Kumar 
et al. 2001). Monsanto-Searle (St. Louis, MO) has 
reported an orally compound SC-68448 which 
inhibited αVβ3-mediated endothelial cell prolif-
eration in a dose-dependent manner but did not 
inhibit tumor cell proliferation, suggesting that 
effects on endothelial cell proliferation were not 
due to SC-68448-induced cytotoxicity. SC68448 
was 100-fold more potent as a functional inhibitor 
of αVβ3 versus αIIbβ3 (Carron et al. 2000). Integrin 
αIIBβ3 expressed mainly on platelet membrane 
plays a crucial role in platelet aggregation and 
thrombus formation, and recently was reported to 
have a role in increasing the risk of metastases in 67
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renal cell carcinoma in men (Kallio et al. 2006). 
Haubner and his co-workers reported that 
18F-
Galacto-RGD is a highly αVβ3-selective tracer for 
positron emission tomography (PET) (Haubner 
et al. 2004, 2001). Molecular imaging with 
18F-
Galacto-RGD and PET provides important informa-
tion for planning and monitoring anti-angiogenic 
therapies targeting the αVβ3 integrin (Beer et al. 
2006). Meerovitch et al. demonstrated BCH-14661 
and BCH-15046, RGD peptidomimetic compounds 
are as apoptotic inducers for endothelial cells by 
causing cell detachment-dependent when cells are 
grown on RGD-containing integrin ligand vitro-
nectin and ﬁ  bronectin. BCH-14661 was speciﬁ  c for 
integrin αVβ3, whereas BCH-15046 nonselectively 
antagonized αVβ3, αVβ5, and α5β1 (Meerovitch 
et al. 2003). A 20 amino acid N-terminal peptide of 
angiocidin was reported to promote α2β1- depen-
dent adhesion of K562 cells, disrupt human umbil-
ical vein endothelial cell tube formation and inhibit 
tumour growth as well as angiogenesis in a mouse 
model (Sabherwal et al. 2006). Angiocidin has also 
been reported to inhibit angiogenesis through bind-
ing collagen and integrin α2β1 present on many 
tumour cells (Sabherwal et al. 2006).
The most selective nonpeptidic α5β1 antagonist 
SJ749 showed a reduced proliferation of astrocy-
toma cell lines dependent on α5β1 expression levels 
and cell culture conditions, underlining the impor-
tance of α5β1 as a target for anticancer therapies 
(Marinelli et al. 2005; Maglott et al. 2006). A 
non—peptide RGD mimetic, S36578-2, was also 
developed and demonstrated as highly selective 
antagonist of both αVβ3 and αVβ5 integrins that was 
able to induce detachment, caspase-8 activation, 
and apoptosis in human umbilical endothelial cells 
(HUVECs) plated on vitronectin (Maubant et al. 
2006). Reinmuth and his co-works demonstrated 
that S-247, another αVβ3/αVβ5 integrin antagonist, 
showed signiﬁ  cant antimetastatic and antiangio-
genic activity and impaired both endothelial and 
hVSMC/pericyte function in vitro and in vivo 
(Reinmuth et al. 2003; Harms et al. 2004).
The integrin-induced signaling cascades have also 
been demonstrated to impact tumor cell survival, cell 
migration, and angiogenesis. It is known that trans-
forming growth factor (TGF)-beta suppresses breast 
cancer formation by preventing cell cycle progres-
sion in mammary epithelial cells (MECs). During 
the course of mammary tumorigenesis, genetic and 
epigenetic changes negate the cytostatic actions of 
TGF-beta, thus enabling TGF-beta to promote the 
acquisition and development of metastatic pheno-
types. TGF-β stimulation can induce αVβ3 integrin 
expression in a manner that coincides with epithelial-
mesenchymal transition (EMT) in MECs. Introduc-
tion of siRNA against β3 integrin can block TGF-β 
induction and also prevent TGF-β stimulation of 
EMT in MECs (Galliher and Schiemann, 2006). 
Therefore, antagonists of growth factor receptors 
(Cardones et al. 2006; Wick et al. 2006) can be used 
for anti-cancer therapy. Indeed, the recognition of 
potent, sequence-selective gene inhibition by siRNA 
oligonucleotides and rapid adoption as the tool of 
choice in cell culture has generated the expectation 
for their use to improve targeted therapeutics 
(Elbashir et al. 2002; Paddison et al. 2003; Carpen-
ter and Sabatini, 2004; Ganju and Hall, 2004). The 
prospects of siRNA to be a therapeutic tool were 
enhanced by their double-stranded RNA (dsRNA) 
oligonucleotide nature, resembling antisense, ribo-
zymes and gene therapy (Song et al. 2003; Davidson 
et al. 2004). Silencing integrin αV expression by 
siRNA can inhibit proliferation and induce apoptosis 
in integrin αV over-expressing MDA-MB-435 
human breast cancer cells (Cao et al. 2006). Lip-
scomb and his co-workers demonstrated that siRNA 
oligonucleotides targeted to either subunit of the α6β4 
integrin reduced cell surface expression of this inte-
grin and resulted in decreased invasion of MDA-
MB-231 breast carcinoma cells (Lipscomb et al. 
2003). Recently gene transfer of antisense αV and β3 
expression vectors was demonstrated to downregu-
late αV and β3 in HepG2 tumours established in nude 
mice, inhibit tumour vascularization and growth, and 
enhance tumour cell apoptosis, suggesting that anti-
sense gene therapy targeting αV integrins could be 
as an approach to treat hepatocellular carcinomas (Li 
et al. 2007).
A study using SUM-159 breast carcinoma cell 
line showed that decreased expression of the α6β4 
integrin led to enhanced apoptosis. Recombinant 
VEGF is able to signiﬁ  cantly inhibit the cell death 
observed in the β4-deﬁ  cient cell line. The speciﬁ  c-
ity of α6β4 in both in vitro and in vivo assays 
showed that reexpression of the β4 subunit into the 
β4-deﬁ  cient cell line could rescue the functional 
phenotype (Lipscomb et al. 2005).
Conclusions
In this review the potential roles of integrin in tumor 
progression and cancer were discussed. Evidence 
presented here indicates that integrins represent 68
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highly appropriate pharmacological targets as based 
upon the beneﬁ  cial effect of integrin antibodies and 
antagonists in cancer treatment. A number of the 
integrin antibodies and antagonists are now in 
clinical trials, determining their effect on angiogen-
esis, metastasis and tumour growth (Table 2).
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